82 related articles for article (PubMed ID: 16264879)
1. Should paclitaxel be combined with epirubicin or carboplatin as first-line chemotherapy for advanced breast cancer?
Gupta S
Nat Clin Pract Oncol; 2005 Feb; 2(2):80-1. PubMed ID: 16264879
[No Abstract] [Full Text] [Related]
2. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
du Bois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; Costa S; Schroeder W; Kimmig R; Pujade-Lauraine E; ; ;
J Clin Oncol; 2006 Mar; 24(7):1127-35. PubMed ID: 16505432
[TBL] [Abstract][Full Text] [Related]
3. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.
Gennari A; Amadori D; De Lena M; Nanni O; Bruzzi P; Lorusso V; Manzione L; Conte PF
J Clin Oncol; 2006 Aug; 24(24):3912-8. PubMed ID: 16921042
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
Papadimitriou CA; Bafaloukos D; Bozas G; Kalofonos H; Kosmidis P; Aravantinos G; Fountzilas G; Dimopoulos MA;
Gynecol Oncol; 2008 Jul; 110(1):87-92. PubMed ID: 18455782
[TBL] [Abstract][Full Text] [Related]
7. Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group.
Koutras AK; Fountzilas G; Dafni U; Dimopoulos MA; Pectasides D; Klouvas G; Papakostas P; Kosmidis P; Samantas E; Gogas H; Briasoulis E; Vourli G; Petsas T; Xiros N; Kalofonos HP;
Anticancer Res; 2008; 28(5B):2913-20. PubMed ID: 19031934
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
De Giorgi U; Giannini M; Frassineti L; Kopf B; Palazzi S; Giovannini N; Zumaglini F; Rosti G; Emiliani E; Marangolo M
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1165-9. PubMed ID: 16682141
[TBL] [Abstract][Full Text] [Related]
9. Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biology.
Warm M; Kates R; Thomas A; Fischer T; Harbeck N
Anticancer Res; 2009 Jul; 29(7):2675-80. PubMed ID: 19596945
[TBL] [Abstract][Full Text] [Related]
10. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
Torrisi R; Balduzzi A; Ghisini R; Rocca A; Bottiglieri L; Giovanardi F; Veronesi P; Luini A; Orlando L; Viale G; Goldhirsch A; Colleoni M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):667-72. PubMed ID: 18064460
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Kalofonos HP; Dafni U; Papadimitriou C; Bafaloukos D; Papakostas P; Kalogera-Fountzila A; Gogas H; Aravantinos G; Moulopoulos LA; Economopoulos T; Pectasides D; Maniadakis N; Siafaka V; Briasoulis E; Christodoulou C; Tsavdaridis D; Makrantonakis P; Razis E; Kosmidis P; Skarlos D; Dimopoulos MA
Ann Oncol; 2004 Oct; 15(10):1517-26. PubMed ID: 15367413
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
[TBL] [Abstract][Full Text] [Related]
13. Impact of tumor biological factors on response to pre-operative epirubicin and paclitaxel chemotherapy in primary breast cancer.
Warm M; Kates R; Mallmann P; Dick M; Nawroth F; Harbeck N; Paepke S; Thomas A
Anticancer Res; 2007; 27(2):1031-8. PubMed ID: 17465239
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
15. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
[TBL] [Abstract][Full Text] [Related]
16. Is it time for some new approaches for treating advanced ovarian cancer?
McGuire WP
J Natl Cancer Inst; 2006 Aug; 98(15):1024-6. PubMed ID: 16882933
[No Abstract] [Full Text] [Related]
17. Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Nisticò C; Bria E; Cuppone F; Fornier M; Sperduti I; Carpino A; Pace A; Cognetti F; Terzoli E
Anticancer Drugs; 2007 Jul; 18(6):687-92. PubMed ID: 17762397
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy protocol with taxol increase survival by 31 percent].
Krankenpfl J; 2002; 40(7-9):226. PubMed ID: 12514866
[No Abstract] [Full Text] [Related]
19. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224
[TBL] [Abstract][Full Text] [Related]
20. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
